This information is provided directly by researchers and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information.

Not provided at time of registration

Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.  

The recruitment start and end dates are as follows:

Interventional

Intervention Type : Drug
Intervention Description : Participants are randomly allocated to mirtazapine or placebo and separately to folic acid or placebo 1. Mirtazapine or placebo 2. Folic acid or placebo Both as add-on therapies to ongoing antipsychotic treatment

Both allocated medicines are taken orally for 12 weeks with a 2-week tapering period for mirtazapine on completion of the trial. The dose of mirtazapine is 30mg and of folic acid 400 - 500microg. (Participants for whom random allocation of folic acid/placebo is not appropriate can take part in the trial and be randomly allocated to lamotrigine or placebo only.)

1. Diagnosis of DSM-IV schizophrenia 2. Active psychotic symptoms - i.e. hallucinations, delusions, thought disorder3. Inpatient or outpatient4. Aged 18 to 70 years. 5. Able and willing to consent to participate 6. Minimum score on PANSS 607. Drug treatment stable8. Currently taking effective dose of antipsychotic 9. Adjunctive mirtazapine appears reasonable and both investigator and patient are uncertain whether it will offer any benefit 10. Clinically appropriate to change or augment treatment. Participants for whom random allocation of folic acid or placebo is not appropriate will be allocated mirtazapine or placebo only.

Ammended 22/09/10:4. 16-70 years

1. Not meeting criteria for current manic episode including schizoaffective disorder2. No antidepressant treatment within last two weeks and not considering treatment for depression 3. Not taking clozapine4. No contraindication to investigational medicinal products5. Not pregnant, breast-feeding or planning a pregnancy

Below are the locations for where you can take part in the trial. Please note that not all sites may be open.

• University of Oxford
  Oxford
  OX3 7JX
  

This information has not yet been provided by the study team. You'll have an opportunity to discuss any risks and benefits that may be associated with this study prior to consenting to taking part.

Prof John Geddes

The study is sponsored by University of Oxford (UK) and funded by Stanley Medical Research Institute (USA).